- October 3, 2023
A new study from Associate Dean of Research Alison Cuellar found that independent practices experienced a smaller drop in patient volume than consolidated practices during the height of the Covid-19 pandemic.
- March 27, 2023
Braun is a leading expert on private equity investments in health care and studies how private equity ownership impacts the quality of patient care in facilities like nursing homes or rehabilitation centers. Braun credits his experience at Mason for giving him a platform to grow into a national researcher and health policy leader.
- October 19, 2022
George Mason Associate Professor of Health Administration and Policy discusses the importance of job-protected paid leave.
- October 3, 2022
Anand Discusses Research on Paid Family Leave with U.S. Policymakers
- Fierce Healthcare: Affiliate faculty member Peter Kongstvedt is quoted in an article on COVID-19 vaccine coverage questions for insurersSeptember 8, 2022
COVID vaccine coverage questions abound for health insurers
- May 6, 2022
Paid leave mandates reduce likelihood of decreasing paid work hours after a spouse’s health shock, study shows.
- May 7, 2022
Paid leave policies do not always include job protection: US President's 2022 Economic Report
- January 7, 2022
CHHS welcomes Dr. Jeah Jung to the Health Administration and Policy faculty. Jung brings research expertise in health economics, health policy, and health disparities.
- Thu, 01/06/2022 - 17:06
- November 22, 2021
In a recent study, George Mason University Associate Professor Hong Xue, PhD and colleagues evaluated the impact of ending market exclusivity for brand-name statin drugs. The first study to comprehensively assess the economic impact of generic competition for statins found that ending market exclusivity for statins saves U.S. $12 billion and individuals nearly $1,000 annually.